Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Astria Therapeutics, Inc. | Chief Commercial Officer | Stock Option (Right to Buy) | 175K | Feb 8, 2024 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ATXS | Astria Therapeutics, Inc. | Feb 8, 2024 | 1 | $0 | 4 | Feb 12, 2024 | Chief Commercial Officer |
ATXS | Astria Therapeutics, Inc. | Jun 2, 2023 | 1 | $0 | 4 | Jun 6, 2023 | Chief Commercial Officer |
ATXS | Astria Therapeutics, Inc. | Mar 1, 2022 | 1 | $0 | 4 | Mar 3, 2022 | Chief Commercial Officer |
ATXS | Astria Therapeutics, Inc. | Dec 28, 2021 | 2 | $0 | 5 | Feb 10, 2022 | Chief Commercial Officer |
ATXS | Astria Therapeutics, Inc. | Nov 19, 2021 | 1 | $670 | 4 | Nov 23, 2021 | Chief Commercial Officer |
ATXS | CATABASIS PHARMACEUTICALS INC | Jun 2, 2021 | 1 | $0 | 4 | Jun 2, 2021 | Chief Commercial Officer |